Streetbeat News

Products Services

BLFS

BioLife Solutions projects its 2024 revenue to be between $95.5 million and $100 million, excluding income from its freezer business. This forecast provides insight into the company's financial health and strategic focus away from its freezer segment.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:44 pm

KNW

Know Labs, Inc. (NYSE:KNW) has secured a funding agreement with Lind Global Fund II LP for up to $12 million to accelerate its non-invasive medical diagnostic technology development. The initial $4 million funding is through convertible secured notes, with provisions for conversion into shares at a premium and issuance of a warrant for purchasing additional shares. This investment aims to support Know Labs' efforts in hardware development, clinical research, algorithm development, and intellectual property expansion, particularly for its wearable continuous glucose monitor pending FDA clearance.

Portfolio Pulse from Happy Mohamed

February 29, 2024 | 9:42 pm

ADSK

Autodesk, Inc. (NASDAQ:ADSK) shares rose after reporting Q4 earnings of $2.09 per share and sales of $1.47 billion, surpassing analyst expectations. Subscription and design revenue showed significant growth. The company is focusing on developing lifecycle solutions with Autodesk's Data Model and leading in 3D generative AI. Autodesk provided an earnings outlook for Q1 and fiscal year 2025, slightly below some analyst estimates.

Portfolio Pulse from Erica Kollmann

February 29, 2024 | 9:37 pm

FDMT

4D Molecular Therapeutics (4DMT) reported a narrower FY23 EPS loss of $(2.58) compared to $(3.32) YoY, and positive interim data from its Phase 2 PRISM study on 4D-150 for wet AMD, indicating progression to Phase 3 in Q1 2025. Positive data were also reported for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease. Strategic partnerships with Astellas Pharma and Arbor Biotechnologies were highlighted. An upsized public offering raised $300 million, extending operational runway into H1 2027. The company anticipates key milestones across its portfolio in 2024.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:35 pm

FBIN

Fortune Brands Innovations, Inc. (NYSE:FBIN) has acquired SpringWell Water Filtration Systems for approximately $105 million, enhancing its presence in the high-growth water filtration market. This acquisition is expected to provide Fortune Brands with increased strategic exposure to recurring revenue streams and digital marketing expertise, contributing to its whole home water ecosystem. SpringWell has shown significant growth since its inception, with a double-digit five-year CAGR, and is anticipated to deliver accretive EBITDA margins to Fortune Brands.

Portfolio Pulse from Happy Mohamed

February 29, 2024 | 9:27 pm

AXNX

MDT

Axonics, Inc. (NASDAQ:AXNX) has been notified of a complaint filed by Medtronic (NYSE:MDT) with the U.S. International Trade Commission (ITC) and a parallel action in U.S. District Court, alleging infringement of two Medtronic patents related to MRI compatibility in implantable medical devices. Axonics CEO Raymond W. Cohen asserts the claims aim to stifle competition and protect Medtronic's market position, emphasizing Axonics' commitment to innovation and market leadership in sacral neuromodulation therapy.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:20 pm

TSLA

Tesla Inc (NASDAQ:TSLA) began Cybertruck deliveries in November 2023, with over one million reservations. Celebrities like Jay-Z, Beyoncé, and Alexis Ohanian are among the first owners, enhancing Tesla's brand awareness through their high-profile endorsements. Tesla CEO Elon Musk reacted positively to Jay-Z's customized matte black Cybertruck on social media.

Portfolio Pulse from Chris Katje

February 29, 2024 | 9:19 pm

MRK

PMVP

PMV Pharmaceuticals reported its FY23 financial results, showing a narrower net loss of $69.0 million compared to $73.3 million in FY22. The company had $228.6 million in cash and equivalents, a slight decrease from $243.5 million the previous year. R&D expenses increased to $55.9 million, primarily due to the development of rezatapopt. G&A expenses slightly decreased to $24.2 million. The report also mentions KEYTRUDA, a trademark of Merck Sharp & Dohme LLC.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:19 pm

RCEL

AVITA Medical has officially submitted its response to the FDA, which resumes the review process for the RECELL GO PMA Supplement. This step is crucial for the company as it moves closer to potentially getting approval for RECELL GO, a product that could significantly impact its market presence and financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:02 pm

AMD

AMD shares are trading higher, potentially due to increased momentum in the AI chip sector.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:00 pm